

Supplementary Online Content

Goldstein LB, Lennihan L, Rabadi MJ, et al. Effect of dextroamphetamine on poststroke motor recovery: a randomized clinical trial. *JAMA Neurol*. Published online August 27, 2018. doi:10.1001/jamaneurol.2018.2338

eFigure. Stratification of Participants by Stroke Severity and Type

eTable 1. Baseline Demographics and Participant Characteristics

eTable 2. Mean National Institutes of Health Stroke Scale Score (SEM)

eTable 3. Mean Canadian Neurological Scale Score (SEM)

eTable 4. Mean Functional Independence Measure Score (SEM)

eTable 5. Mean Ambulation Distance (6-Minute Walk Test) (SEM)

eTable 6. Mean Ambulation Speed (6-Minute Walk Test) (SEM)

eTable 7. Mean Research Arm Test Score (SEM)

eTable 8. Mean Mini-Mental State Examination Score (SEM)

eTable 9. Mean Beck Depression Index Score (SEM)

eTable 10. Mean Stroke Impact Scale Score (SEM)

This supplementary material has been provided by the authors to give readers additional information about their work.

Amphetamine-Enhanced Stroke Recovery Trial Supplement

Supplemental Table 1. Baseline Demographics and Participant Characteristics

Strata	Severe-Cortical		Severe-Subcortical		Moderate-Cortical		Moderate-Subcortical		Total		p value*
	A (N=8)	P (N=9)	A (N=12)	P (N=13)	A (N=6)	P (N=4)	A (N=6)	P (N=6)	A (N=32)	P (N=32)	
Characteristics											
Age											0.6869
Median	60.0	61.0	70.5	71.0	63.5	70.0	61.5	57.5	67.5	65.5	
Q1, Q3	54.5, 71.0	59.0, 73.0	66.5, 78.0	53.0, 79.0	50.0, 73.0	64.5, 78.5	53.0, 78.0	56.0, 65.0	57.0, 77.5	56.0, 75.0	
Sex											0.4513
Male	6 (75.0%)	4 (44.4%)	6 (50.0%)	7 (53.8%)	4 (66.7%)	3 (75.0%)	3 (50.0%)	2 (33.3%)	19 (59.4%)	16 (50.0%)	
Female	2 (25.0%)	5 (55.6%)	6 (50.0%)	6 (46.2%)	2 (33.3%)	1 (25.0%)	3 (50.0%)	4 (66.7%)	13 (40.6%)	16 (50.0%)	
Race											0.1061
White	8 (100.0%)	8 (88.9%)	9 (75.0%)	9 (69.2%)	5 (83.3%)	4 (100.0%)	4 (66.7%)	2 (33.3%)	26 (81.3%)	23 (71.9%)	
Black	0 (0.0%)	1 (11.1%)	0 (0.0%)	3 (23.1%)	1 (16.7%)	0 (0.0%)	1 (16.7%)	4 (66.7%)	2 (6.3%)	8 (25.0%)	
Other	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (7.7%)	0 (0.0%)	0 (0.0%)	1 (16.7%)	0 (0.0%)	2 (6.3%)	1 (3.1%)	
Hispanic	0 (0.0%)	0 (0.0%)	2 (16.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (6.3%)	0 (0.0%)	
Lives with											0.3989
Spouse	6 (75.0%)	4 (44.4%)	5 (41.7%)	8 (61.5%)	4 (66.7%)	2 (50.0%)	2 (33.3%)	2 (33.3%)	17 (53.1%)	16 (50.0%)	
Significant Other	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (16.7%)	1 (16.7%)	1 (3.1%)	1 (3.1%)	
Other Adult	1 (12.5%)	3 (33.3%)	2 (16.7%)	2 (15.4%)	0 (0.0%)	2 (50.0%)	1 (16.7%)	2 (33.3%)	4 (12.5%)	9 (28.1%)	
None of the Above	1 (12.5%)	2 (22.2%)	5 (41.7%)	3 (23.1%)	2 (33.3%)	0 (0.0%)	2 (33.3%)	1 (16.7%)	10 (31.3%)	6 (18.8%)	
Living condition											0.8371
House	6 (75.0%)	7 (77.8%)	8 (66.7%)	9 (69.2%)	6 (100.0%)	3 (75.0%)	3 (50.0%)	3 (50.0%)	23 (71.9%)	22 (68.8%)	
Apartment	2 (25.0%)	2 (22.2%)	3 (25.0%)	3 (23.1%)	0 (0.0%)	1 (25.0%)	3 (50.0%)	2 (33.3%)	8 (25.0%)	8 (25.0%)	
Assisted Living	0 (0.0%)	0 (0.0%)	1 (8.3%)	1 (7.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (16.7%)	1 (3.1%)	2 (6.3%)	
Lesion Type											0.3058
Missing	0 (.%)	0 (.%)	0 (.%)	0 (.%)	0 (.%)	0 (.%)	0 (.%)	1 (.%)	0 (.%)	1 (.%)	
Ischemic	8 (100.0%)	8 (88.9%)	12 (100.0%)	13 (100.0%)	6 (100.0%)	4 (100.0%)	6 (100.0%)	5 (100.0%)	32 (100.0%)	30 (96.8%)	
Ischemic with Hemorrhage	0 (0.0%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (3.2%)	

Supplemental Table 1. Baseline Demographics and Participant Characteristics

Strata	Severe-Cortical		Severe-Subcortical		Moderate-Cortical		Moderate-Subcortical		Total		p value*
	A (N=8)	P (N=9)	A (N=12)	P (N=13)	A (N=6)	P (N=4)	A (N=6)	P (N=6)	A (N=32)	P (N=32)	
Characteristics											
Lesion Location											0.4587
Missing	0 (.%)	0 (.%)	0 (.%)	0 (.%)	0 (.%)	0 (.%)	0 (.%)	1 (.%)	0 (.%)	1 (.%)	
Supratentorial Cortical	0 (0.0%)	1 (11.1%)	0 (0.0%)	1 (7.7%)	3 (50.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	3 (9.4%)	3 (9.7%)	
Supratentorial Deep	0 (0.0%)	0 (0.0%)	9 (75.0%)	9 (69.2%)	0 (0.0%)	0 (0.0%)	4 (66.7%)	5 (100.0%)	13 (40.6%)	14 (45.2%)	
Supratentorial Cortical and Deep	8 (100.0%)	8 (88.9%)	3 (25.0%)	2 (15.4%)	3 (50.0%)	2 (50.0%)	2 (33.3%)	0 (0.0%)	16 (50.0%)	12 (38.7%)	
Brainstem/Cerebellum	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (6.5%)	
Prior Stroke											0.9617
Missing	0 (.%)	0 (.%)	0 (.%)	1 (.%)	0 (.%)	0 (.%)	0 (.%)	0 (.%)	0 (.%)	1 (.%)	
No Prior Stroke	8 (100.0%)	9 (100.0%)	12 (100.0%)	11 (91.7%)	4 (66.7%)	2 (50.0%)	4 (66.7%)	5 (83.3%)	28 (87.5%)	27 (87.1%)	
Prior Stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	2 (33.3%)	2 (50.0%)	2 (33.3%)	1 (16.7%)	4 (12.5%)	4 (12.9%)	
Target Deficit											0.9548
Missing	0 (.%)	0 (.%)	1 (.%)	0 (.%)	0 (.%)	0 (.%)	1 (.%)	1 (.%)	2 (.%)	1 (.%)	
Gait	7 (87.5%)	8 (88.9%)	11 (100.0%)	12 (92.3%)	3 (50.0%)	4 (100.0%)	4 (80.0%)	2 (40.0%)	25 (83.3%)	26 (83.9%)	
Arm	1 (12.5%)	1 (11.1%)	0 (0.0%)	1 (7.7%)	3 (50.0%)	0 (0.0%)	1 (20.0%)	3 (60.0%)	5 (16.7%)	5 (16.1%)	
Oxfordshire Classification											0.5984
Missing	0 (.%)	0 (.%)	1 (.%)	0 (.%)	0 (.%)	1 (.%)	0 (.%)	0 (.%)	1 (.%)	1 (.%)	
LACI, LACS	0 (0.0%)	0 (0.0%)	7 (63.6%)	6 (46.2%)	0 (0.0%)	1 (33.3%)	5 (83.3%)	5 (83.3%)	12 (38.7%)	12 (38.7%)	
PACI, PACS	8 (100.0%)	9 (100.0%)	4 (36.4%)	6 (46.2%)	6 (100.0%)	2 (66.7%)	1 (16.7%)	1 (16.7%)	19 (61.3%)	18 (58.1%)	
POCI, POCS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (3.2%)	

*P-value comparing distributions between *d*-Amphetamine (A) vs. Placebo (P)

Supplemental Table 2. Mean NIH-Stroke Scale (SEM)

<i>Strata</i>	<i>Baseline</i>	<i>End of Treatment</i>	<i>3-Month</i>	<i>Baseline - 3 Month Difference</i>
Severe Cortical				
<i>d</i> -Amphetamine	16.75 (1.52)	14.75 (1.95)	11.00 (2.23)	5.75 (1.51)
Placebo	17.11 (2.38)	16.86 (2.85)	16.50 (1.85)	5.50 (2.18)
p-value	0.961	0.486	0.050	0.392
Severe Subcortical				
<i>d</i> -Amphetamine	12.83 (1.21)	10.33 (1.02)	9.00 (1.26)	3.91 (1.13)
Placebo	13.31 (0.96)	9.08 (1.01)	8.67 (0.67)	4.58 (0.86)
p-value	0.547	0.468	0.852	0.475
Moderate Cortical				
<i>d</i> -Amphetamine	13.83 (4.45)	8.83 (3.07)	6.00 (3.02)	7.83 (1.94)
Placebo	8.75 (1.44)	3.25 (1.60)	4.00 (2.74)	4.75 (3.04)
p-value	0.748	0.238	0.829	0.668
Moderate Subcortical				
<i>d</i> -Amphetamine	9.67 (2.04)	6.67 (1.50)	7.33 (1.87)	2.33 (1.12)
Placebo	10.17 (3.02)	7.20 (3.28)	6.00 (1.61)	5.60 (2.04)
p-value	0.747	0.711	0.462	0.232
Total				
<i>d</i> -Amphetamine	13.41 (1.11)	10.47 (0.98)	8.61 (1.00)	4.84 (0.75)
Placebo	13.22 (1.06)	9.86 (1.30)	8.64 (1.01)	4.96 (0.77)
p-value	0.856	0.476	0.941	0.974

Supplemental Table 3. Mean Canadian Neurological Score (SEM)

<i>Strata</i>	<i>Baseline</i>	<i>End of Treatment</i>	<i>3-Month</i>	<i>Baseline - 3 Month Difference</i>
Severe Cortical				
<i>d</i> -Amphetamine	4.50 (0.65)	6.13 (0.54)	6.81 (0.58)	-2.31 (0.43)
Placebo	5.06 (0.61)	5.36 (0.97)	5.70 (0.46)	-0.90 (0.98)
p-value	0.769	0.177	0.102	0.262
Severe Subcortical				
<i>d</i> -Amphetamine	5.25 (0.19)	6.42 (0.32)	7.05 (0.51)	-1.73 (0.48)
Placebo	5.46 (0.35)	7.33 (0.35)	8.00 (0.30)	-2.46 (0.29)
p-value	0.637	0.070	0.163	0.335
Moderate Cortical				
<i>d</i> -Amphetamine	6.42 (1.01)	7.92 (0.99)	8.42 (1.01)	-2.00 (0.82)
Placebo	6.38 (0.63)	8.88 (0.66)	10.00 (0.50)	-3.63 (0.66)
p-value	0.829	0.667	0.321	0.159
Moderate Subcortical				
<i>d</i> -Amphetamine	7.75 (0.78)	9.08 (0.68)	9.58 (0.57)	-1.83 (0.56)
Placebo	7.50 (0.67)	8.40 (1.00)	8.30 (0.90)	-0.90 (0.70)
p-value	0.744	0.582	0.230	0.408
Total				
<i>d</i> -Amphetamine	<i>d</i> -Amphetamine	<i>d</i> -Amphetamine	<i>d</i> -Amphetamine	<i>d</i> -Amphetamine
Placebo	5.84 (0.30)	7.25 (0.40)	7.92 (0.35)	-2.04 (0.33)
p-value	0.909	0.645	0.748	0.662

Supplemental Table 4. Mean Functional Independence Measure (SEM)

<i>Strata</i>	<i>Baseline</i>	<i>End of Treatment</i>	<i>3-Month</i>	<i>Baseline - 3 Month Difference</i>
Severe Cortical				
<i>d</i> -Amphetamine	51.38 (7.21)	74.75 (8.70)	94.25 (10.21)	-42.88 (5.56)
Placebo	48.44 (5.69)	62.29 (9.43)	90.40 (8.93)	-39.00 (4.31)
p-value	0.885	0.487	0.769	0.378
Severe Subcortical				
<i>d</i> -Amphetamine	54.83 (4.81)	80.17 (6.53)	87.73 (8.73)	-32.73 (4.82)
Placebo	54.92 (3.69)	80.08 (4.40)	93.08 (6.96)	-37.42 (4.53)
p-value	0.957	0.954	0.805	0.406
Moderate Cortical				
<i>d</i> -Amphetamine	69.83 (7.61)	102.33 (7.42)	112.33 (6.46)	-42.50 (4.46)
Placebo	80.25 (8.02)	100.50 (6.46)	115.75 (4.27)	-35.50 (6.25)
p-value	0.392	0.915	0.831	0.670
Moderate Subcortical				
<i>d</i> -Amphetamine	70.83 (11.86)	94.33 (11.15)	109.00 (12.82)	-38.17 (12.50)
Placebo	78.00 (6.28)	95.00 (8.37)	98.60 (9.34)	-22.00 (5.92)
p-value	0.631	0.855	0.273	0.273
Total				
Amphetamine	59.78 (3.77)	85.63 (4.34)	98.29 (5.04)	-38.29 (3.31)
Placebo	60.59 (3.41)	81.21 (4.17)	97.12 (4.26)	-34.46 (2.84)
p-value	0.819	0.588	0.597	0.461

Supplemental Table 5. Mean Ambulation Distance (6-minute Walk Test, feet; SEM)

<i>Strata</i>	<i>Baseline</i>	<i>End of Treatment</i>	<i>3-Month</i>	<i>Baseline - 3 Month Difference</i>
Severe Cortical				
<i>d</i> -Amphetamine	93.50 (72.00)	283.75 (125.56)	385.50 (153.40)	-292.00 (86.55)
Placebo	115.78 (82.13)	522.83 (265.91)	385.25 (274.89)	-312.75 (226.12)
p-value	0.764	0.897	0.396	0.497
Severe Subcortical				
<i>d</i> -Amphetamine	19.25 (7.60)	236.67 (69.98)	360.82 (128.17)	-339.82 (122.69)
Placebo	154.83 (131.57)	184.58 (28.83)	314.58 (132.47)	-159.75 (47.85)
p-value	0.479	0.840	0.951	0.479
Moderate Cortical				
<i>d</i> -Amphetamine	510.50 (233.82)	652.17 (217.11)	761.50 (226.07)	-251.00 (158.63)
Placebo	407.33 (258.47)	506.00 (223.55)	806.50 (202.27)	-448.67 (377.31)
p-value	0.796	0.670	0.670	0.606
Moderate Subcortical				
<i>d</i> -Amphetamine	241.83 (139.90)	456.67 (197.15)	837.00 (283.10)	-595.17 (207.46)
Placebo	212.50 (104.42)	335.20 (135.64)	402.20 (199.00)	-163.40 (111.92)
p-value	0.872	0.647	0.361	0.144
Total				
<i>d</i> -Amphetamine	171.66 (60.00)	367.59 (70.32)	536.90 (95.21)	-359.71 (70.07)
Placebo	179.90 (65.26)	335.26 (73.56)	422.12 (93.48)	-222.13 (64.14)
p-value	0.926	0.732	0.478	0.156

Supplemental Table 6. Mean Ambulation Speed (6-minute Walk Test, feet/minute; SEM)

<i>Strata</i>	<i>Baseline</i>	<i>End of Treatment</i>	<i>3-Month</i>	<i>Baseline - 3 Month Difference</i>
Severe Cortical				
<i>d</i> -Amphetamine	19.75 (12.29)	34.13 (8.43)	66.13 (26.02)	-46.38 (15.04)
Placebo	30.89 (21.03)	82.67 (41.35)	47.75 (22.29)	-28.25 (13.73)
p-value	0.727	0.699	0.610	0.552
Severe Subcortical				
<i>d</i> -Amphetamine	12.67 (6.88)	64.58 (20.48)	68.91 (20.98)	-55.09 (16.86)
Placebo	30.58 (19.53)	52.92 (19.03)	53.50 (21.68)	-22.92 (7.19)
p-value	0.445	0.954	0.758	0.310
Moderate Cortical				
<i>d</i> -Amphetamine	65.75 (34.08)	115.83 (33.04)	129.83 (31.83)	-32.00 (7.45)
Placebo	54.67 (25.98)	96.50 (36.59)	144.75 (32.18)	-100.33 (48.83)
p-value	1.000	0.394	0.522	0.289
Moderate Subcortical				
<i>d</i> -Amphetamine	172.67 (129.19)	100.67 (36.64)	137.83 (47.82)	34.83 (120.77)
Placebo	60.83 (18.49)	71.20 (19.32)	67.20 (32.33)	-11.60 (19.54)
p-value	0.936	0.715	0.273	0.273
Total				
<i>d</i> -Amphetamine	53.63 (27.21)	73.34 (12.74)	93.32 (15.30)	-30.90 (25.22)
Placebo	39.13 (10.80)	69.37 (13.60)	69.92 (14.66)	-31.13 (9.34)
p-value	0.788	0.879	0.335	0.214

Supplemental Table 7. Mean Action Research Arm Test (SEM)

<i>Strata</i>	<i>Baseline</i>	<i>End of Treatment</i>	<i>3-Month</i>	<i>Baseline - 3 Month Difference</i>
Severe Cortical				
<i>d</i> -Amphetamine	42.88 (9.36)	53.38 (8.88)	62.14 (8.45)	-13.14 (9.01)
Placebo	57.88 (3.54)	65.00 (8.00)	57.75 (0.75)	-4.50 (3.57)
p-value	0.523	0.299	0.679	0.921
Severe Subcortical				
<i>d</i> -Amphetamine	57.25 (0.25)	58.67 (1.10)	59.55 (2.16)	-2.27 (1.89)
Placebo	58.85 (1.97)	67.75 (5.14)	76.67 (5.78)	-17.33 (5.42)
p-value	0.726	0.271	0.022	0.011
Moderate Cortical				
<i>d</i> -Amphetamine	77.00 (10.39)	77.83 (10.00)	81.00 (12.04)	-9.40 (6.81)
Placebo	76.00 (19.00)	90.75 (12.87)	105.25 (8.75)	-26.33 (16.60)
p-value	0.684	0.334	0.095	0.341
Moderate Subcortical				
<i>d</i> -Amphetamine	84.50 (9.39)	91.50 (12.91)	92.17 (11.44)	-7.67 (4.92)
Placebo	73.40 (11.25)	74.00 (10.93)	74.00 (11.26)	-0.60 (0.40)
p-value	0.444	0.714	0.389	0.370
Total				
<i>d</i> -Amphetamine	62.47 (4.30)	67.09 (4.40)	70.62 (4.37)	-7.24 (2.72)
Placebo	62.86 (3.04)	71.46 (4.07)	77.68 (4.58)	-12.83 (3.69)
p-value	0.375	0.271	0.129	0.082

Supplemental Table 8. Mean Mini Mental State Examination (SEM)

<i>Strata</i>	<i>Baseline</i>	<i>End of Treatment</i>	<i>3-Month</i>	<i>Baseline - 3 Month Difference</i>
Severe Cortical				
<i>d</i> -Amphetamine	14.88 (4.50)	19.00 (3.91)	21.38 (3.51)	-6.50 (2.73)
Placebo	17.67 (3.77)	14.83 (5.15)	11.33 (7.31)	-2.00 (3.61)
p-value	0.884	0.398	0.182	0.409
Severe Subcortical				
<i>d</i> -Amphetamine	22.50 (1.28)	25.00 (1.40)	24.36 (1.71)	-1.82 (1.11)
Placebo	21.54 (2.03)	23.67 (1.52)	23.08 (1.67)	-1.83 (1.56)
p-value	0.870	0.601	0.557	0.926
Moderate Cortical				
<i>d</i> -Amphetamine	12.50 (5.64)	18.17 (4.94)	21.83 (2.36)	-9.33 (3.81)
Placebo	27.75 (1.03)	28.50 (0.96)	28.25 (1.03)	-0.50 (2.06)
p-value	0.030	0.194	0.051	0.198
Moderate Subcortical				
<i>d</i> -Amphetamine	19.83 (4.56)	23.33 (2.19)	23.83 (1.90)	-4.00 (3.68)
Placebo	23.50 (0.92)	26.25 (1.89)	23.60 (1.40)	-0.40 (1.91)
p-value	0.747	0.334	1.000	0.646
Total				
<i>d</i> -Amphetamine	18.22 (1.86)	21.91 (1.51)	23.00 (1.20)	-4.90 (1.33)
Placebo	21.59 (1.43)	22.77 (1.63)	22.58 (1.51)	-1.33 (0.98)
p-value	0.270	0.621	0.912	0.119

Supplemental Table 9. Mean Beck Depression Index (SEM)

<i>Strata</i>	<i>Baseline</i>	<i>End of Treatment</i>	<i>3-Month</i>	<i>Baseline - 3 Month Difference</i>
Severe Cortical				
<i>d</i> -Amphetamine	9.86 (2.25)	7.00 (1.38)	10.50 (2.04)	-0.43 (1.56)
Placebo	17.78 (3.33)	11.60 (1.81)	6.50 (2.75)	12.00 (5.28)
p-value	0.071	0.078	0.308	0.037
Severe Subcortical				
<i>d</i> -Amphetamine	12.45 (1.61)	6.67 (1.05)	9.45 (2.29)	3.70 (2.08)
Placebo	11.00 (2.94)	9.45 (1.94)	10.91 (2.63)	-1.90 (1.78)
p-value	0.323	0.286	0.742	0.053
Moderate Cortical				
<i>d</i> -Amphetamine	11.33 (2.46)	9.40 (1.60)	7.50 (1.59)	3.83 (1.92)
Placebo	7.25 (2.29)	4.75 (1.18)	5.00 (1.41)	2.25 (2.87)
p-value	0.336	0.048	0.279	0.520
Moderate Subcortical				
<i>d</i> -Amphetamine	16.17 (3.82)	11.60 (3.78)	11.00 (3.75)	5.17 (3.55)
Placebo	6.83 (1.35)	4.60 (1.63)	9.00 (2.10)	-1.00 (2.17)
p-value	0.076	0.209	0.709	0.272
Total				
<i>d</i> -Amphetamine	12.37 (1.20)	8.19 (0.94)	9.65 (1.21)	3.03 (1.16)
Placebo	11.68 (1.68)	8.16 (1.11)	8.79 (1.41)	1.43 (1.66)
p-value	0.520	0.956	0.507	0.145

Supplemental Table 10. Mean Stroke Impact Scale (SEM)

<i>Strata</i>	<i>Baseline</i>	<i>3-Month</i>	<i>Baseline - 3 Month Difference</i>
Severe Cortical			
<i>d</i> -Amphetamine	31.71 (5.88)	48.13 (6.29)	-14.29 (3.60)
Placebo	35.50 (5.11)	50.00 (5.26)	-13.40 (11.03)
p-value	0.524	0.661	0.871
Severe Subcortical			
<i>d</i> -Amphetamine	30.82 (1.86)	49.60 (4.83)	-20.67 (4.96)
Placebo	29.08 (2.33)	52.09 (4.18)	-21.70 (4.64)
p-value	0.441	0.672	1.000
Moderate Cortical			
<i>d</i> -Amphetamine	52.00 (5.28)	67.00 (4.46)	-15.00 (2.27)
Placebo	43.25 (7.23)	69.50 (0.87)	-26.25 (7.06)
p-value	0.281	0.915	0.201
Moderate Subcortical			
<i>d</i> -Amphetamine	34.33 (4.29)	55.83 (8.13)	-21.50 (5.74)
Placebo	43.50 (6.40)	47.00 (5.98)	-6.60 (5.39)
p-value	0.336	0.361	0.200
Total			
<i>d</i> -Amphetamine	35.97 (2.44)	53.93 (3.11)	-18.04 (2.23)
Placebo	35.57 (2.43)	53.44 (2.74)	-17.58 (3.49)
p-value	0.784	0.892	0.861